Video

Diabetes Meds

Davida Kruger discusses SGLT2 medications—a new class of diabetes drugs—and its mechanism of action and the benefits. Interviewed by Mimi Secor, MS, MEd, APRN, BC, FNP, FAANP

Publish date: December 12, 2013
By
Davida Kruger, MSN, APRN-Bc, BC-ADM
Author and Disclosure Information

 

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

To hear her lecture on “Cost-Effective Diabetes Treatment for the Under-Uninsured,” and earn CE/CME credit, please attend the 2013 MEDS West in Irvine, CA, October 3-5. Click here for complete details.

Recommended Reading

Point/Counterpoint – Should the IADPSG criteria for diagnosing gestational diabetes be adopted now worldwide?
Type 2 Diabetes ICYMI
Analysis: No such thing as ‘benign’ obesity
Type 2 Diabetes ICYMI
Gastric banding benefited overweight, not just obese in type 2 diabetes
Type 2 Diabetes ICYMI
Heart failure exacerbation by saxagliptin called ‘real’
Type 2 Diabetes ICYMI
Bariatric surgery benefits in type 2 diabetes linked to disease duration
Type 2 Diabetes ICYMI
Diet drinks’ link to cardiometabolic disease elusive
Type 2 Diabetes ICYMI
Bromocriptine-QR slashes cardiovascular events in diabetics on metformin
Type 2 Diabetes ICYMI
Body fat and cardiovascular risk: Location, location, location!
Type 2 Diabetes ICYMI
Diabetes morbidity varies with patient age, disease duration
Type 2 Diabetes ICYMI
Healthy diet after diabetes diagnosis improves survival
Type 2 Diabetes ICYMI